CCR7 and rheumatoid arthritis: This study demonstrated that BM-MSCs exert a significant inhibitory action over all monocyte subsets and mDCs from RA patients, potentially affecting their ability to stimulate the immune adaptive response at different levels: BM-MSCs hinder CCR7 upregulation upon cell activation, and this can potentially hamper APCs’ migration into the lymph node; simultaneously, BM-MSCs inhibit the proinflammatory cytokines/chemokines’ production by mDCs and monocytes, which can potentially hamper T cell polarization towards Th1/Th17 and migration to inflamed tissue.